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The prevalence of overweight (body mass index (BMI)
425 kg/m2) and obesity (BMI430 kg/m2) in adults with
schizophrenia is approximately twice that in the general
population and while it has increased in both groups in the
past 30 years, the rate of increase is greater in people with
schizophrenia.1 Weight gain often occurs after initiation of
antipsychotic treatment: over 50% of individuals gain more
than 7% of their initial body weight within the ﬁrst 12
months of treatment,with up to 86% gainingweight with some
types of antipsychotic.2 Comparedwith the general population,
people with schizophrenia consume more fat and reﬁned
carbohydrates and fewer vegetables,3-5 are less physically
active and experience higher levels of deprivation,4-7 all of
which are associated with obesity. The National Institute for
Health and Care Excellence (NICE) recommends that
people with psychosis or schizophrenia, particularly those
taking antipsychotics, should be offered access to a
combined healthy eating and physical activity programme
to aid in the prevention of weight gain and its related
comorbidities, leading to improved quality of life.8 They
should be supported by clinicians to make choices about
antipsychotic medication, informed by discussions of likely
beneﬁts, possible side-effects, such as weight gain and
metabolic disturbance, and impact on other aspects of their
physical health. For those who smoke, help should be
offered to stop smoking.8
The STEPWISE study (STructured lifestyle Education
for People WIth SchizophrEnia, schizoaffective disorder and
ﬁrst episode psychosis; ISRCTN19447796) was commissioned
to evaluate the extent to which a structured lifestyle
education programme can support weight loss, compared
with usual care, when delivered to adults with schizophrenia,
including those with schizoaffective disorder or ﬁrst-episode
psychosis, in a community mental health setting. In pragmatic
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Aims and method The STEPWISE trial (STructured lifestyle Education for People
WIth SchizophrEnia, schizoaffective disorder and ﬁrst episode psychosis) is currently
evaluating a lifestyle education programme in addition to usual care. However, it is
difﬁcult to deﬁne what constitutes ‘usual care’. We aimed to deﬁne ‘usual care’ for
lifestyle management in people with schizophrenia, schizoaffective disorder and ﬁrst-
episode psychosis in STEPWISE study sites. Ten National Health Service (NHS)
mental health trusts participated in a bespoke survey based on the National Institute
for Health and Care Excellence (NICE) guidance.
Results Eight trusts reported offering lifestyle education programmes and nine
offered smoking cessation support. Reported recording of biomedical measures
varied.
Clinical implications Although recommended by NICE, lifestyle education
programmes are not consistently offered across UK NHS mental health trusts.
This highlights missed opportunities to improve the physical health of people with
psychotic illness. Our survey benchmarks ‘usual care’ for the STEPWISE study, against
which changes can be measured. Furthermore, future studies will be able to identify
whether any progress in clinical practice has been made towards achieving the NICE
recommendations.
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trials, practitioners are often allowed ‘considerable leeway
in deciding how to formulate and apply’ the treatment in a
control arm deﬁned as ‘usual care’.9 While the result may be
reﬂective of the care received by patients outside the trial,
there is often variation in care in an active control arm,
which may be difﬁcult to document.10,11 For this reason,
study teams often try to capture the active content of the
control arm of their trials.12 In this paper we describe a
survey of ‘usual care’ for the management of weight and
other lifestyle factors in people with schizophrenia,
schizoaffective disorder and ﬁrst-episode psychosis in the
ten participating study sites.
Method
Research tool
The survey instrument consisted of 14 questions, which
were a combination of closed and open design, with the aim
of eliciting information about the implementation of the
recent NICE guidance on psychosis and schizophrenia at
National Health Service (NHS) mental health trusts in the
UK, and consequently what is offered as ‘usual care’. The
survey was developed for the research study, based on the
physical health aspects of the NICE recommendations in
clinical guideline 178.8 Questions followed the baseline
assessment tool published alongside the NICE guidance.
The instrument was piloted with one study site investigator
(J.M.) on two occasions, and each led to substantial changes
to the tool. For instance, the second iteration revised
questions to ascertain proportions of patients to whom
certain criteria apply, rather than closed questions such as
‘Are patients referred to a healthy eating programme?’ The
ﬁnal version of the tool also clariﬁed which questions
related to all patients with schizophrenia, schizoaffective
disorder and ﬁrst-episode psychosis, and which questions
related to patients with ﬁrst-episode psychosis only (the
questionnaire is included in the Appendix). This is in line
with the additional recommendations speciﬁed in the NICE
guidance for patients with ﬁrst-episode psychosis who have
recently been prescribed antipsychotic medication; these
additional questions were not applicable to the management
of patients with established mental illnesses.
Survey structure
Trusts were initially asked whether they offered a healthy
eating and physical activity programme. Subsequent questions
asked for more information about these programmes,
including whether they were combined or separate for
healthy eating and physical activity; how patients accessed
them; and how often patients were referred to such services.
Additional information was sought on the availability of
smoking cessation services in this population and whether
discussions took place between patients and clinicians prior
to antipsychotic treatment initiation, including beneﬁts of
treatment, interactions with other substances and other
possible side-effects.
In addition, NICE recommend that a number of
physiological measures should be recorded both prior to
the patient starting antipsychotic medication and annually
thereafter. Respondents were asked to comment on how
likely it was that each measure would be recorded at both of
these time points in their trust and how often patients on
antipsychotic medication have their weight recorded.
Sample selection
The STEPWISE trial has ten centres in a variety of urban,
suburban and rural locations across England: Shefﬁeld
Health and Social Care NHS Foundation Trust, Leeds and
York Partnership NHS Foundation Trust, Bradford District
Care NHS Foundation Trust, Greater Manchester West
Mental Health NHS Foundation Trust, South London and
Maudsley NHS Foundation Trust, Sussex Partnership NHS
Foundation Trust, Southern Health NHS Foundation Trust,
Devon Partnership NHS Trust, Somerset Partnership
NHS Foundation Trust and Cornwall Partnership NHS
Foundation Trust. A representative from each centre was
invited to complete the survey.
Respondents
The principal investigators at each of the ten centres for the
STEPWISE trial were initially approached. Some of them
completed the survey themselves, while others delegated to
trust physical health leads or equivalent as they were better
placed to answer the questions. Contact was made via email
in the ﬁrst instance, with an invitation to attend a
teleconference with the STEPWISE research assistant
(L.S.) to complete the survey. Those who did not provide a
response to the invitation within 4 weeks were contacted
again by reminder emails and/or by telephone. Six of the ten
sites’ surveys were completed through discussion via tele-
conference. The remaining four sites’ surveys were completed
independently by a trust representative and written responses
were provided to the STEPWISE research assistant.
No sites required more than one reminder email/
telephone call in order to arrange completion of the survey.
As the survey information was requested from members of a
research team, a favourable ethical opinion from an NHS
Research Ethics Committee was not sought and consent was
unnecessary. Responses provided organisational data only
and did not include any personal data. Responses from all
sites were received between 22 May and 28 October 2015.
Analysis
Descriptive statistics in the form of counts were produced
for quantitative variables. Supporting information provided
by respondents and information yielded from qualitative
questions was summarised in narrative form.
Results
Healthy eating and physical activity programmes
Eight respondents reported that their trust offered
programmes on healthy eating and physical activity, which
were mostly separate programmes. Supplementary inform-
ation indicated that provision was ad hoc and interventions
were rarely standardised. Most respondents reported
routinely inviting patients to access services such as
discounted local gym memberships, cooking groups and
activity groups delivered by local authorities and third-sector
organisations. Two trusts reported offering one-on-one advice
sessions with healthy living advisors or health trainers, but
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the sessions were usually advice-giving and often more
clinically focused rather than looking at the patient’s
physical well-being.
Those trusts that offered trust-led programmes
reported that these were available in principle to all of
their patients rather than speciﬁc groups based on
diagnosis. However, interventions were often accessed
only by certain groups of patients, usually through
particular clinicians or clinics. One trust estimated that
70% of their eligible patients are referred to such services
by mental health professionals, based on recent
Commissioning for Quality and Innovation (CQUIN)
results; other respondents were unaware of routine data
from which they could quantify referrals. Six trusts reported
offering lifestyle advice through open-ended group courses,
three through courses delivered over a ﬁxed period and four
through drop-in sessions.
Smoking cessation advice
Six respondents indicated that patients who smoke were
offered help to stop some of the time, three reported help
was offered all of the time, and one said this was not offered
at all. Respondents who selected ‘some of the time’ were
unable to quantify this, but felt that this occurred most of
the time. Although it varied whether smoking cessation
services were offered by the trusts or external services, most
offered a combination of the two. Seven trusts reported
offering trust-led smoking cessation services, while others
had trained smoking cessation advisors but had no formal
trust-offered service. Most trusts reported signposting out-
patients to external services, some of which were managed by
primary care, with advice leaﬂets available within the trust.
Antipsychotic treatment initiation
Table 1 shows the reported levels of discussion about likely
beneﬁts of treatment, as well as potential weight gain,
diabetes and metabolic side-effects and any other possible
side-effects, across all respondents. Most trusts who
reported that the recommended discussions took place
‘some of the time’ felt that this would be most of the time,
but there was a lack of evidence to support this. One site
reported that discussions would be dependent on the
clinician, but that resources were available to clinicians to
support the discussions. Another site suggested that such
discussions may be part of an ongoing process rather than
all happening in one session, depending on the patient’s
level of capacity.
Table 1 also shows how often respondents reported
discussions taking place regarding the use of alcohol, tobacco,
prescribed and non-prescribed medications and illicit drugs,
at the time of antipsychotic treatment initiation.
Table 2 shows how likely trusts considered that
physiological measures would be recorded prior to treatment
initiation.
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Table 1 Discussions with patients when deciding on antipsychotic treatment (n= 10 NHS trusts)
All of the time Some of the time Not at all
Topic
Likely beneﬁts 7 3 0
Weight gain 5 5 0
Diabetes and metabolic side-effects 3 7 0
Other possible side-effects 5 5 0
Other substances
Alcohol 5 5 0
Tobacco 2 8 0
Other prescribed medications 3 7 0
Non-prescribed medications 0 10 0
Illicit drugs 3 7 0
Table 2 Recording of physiological measures prior to antipsychotic treatment initiation (n= 10 NHS trusts)
Very
likely Likely
Neither likely
nor unlikely Unlikely
Very
unlikely
Weight 3 4 1 2 0
Weight plotted on a chart 1 3 1 3 2
Waist circumference 0 2 3 3 2
Pulse 3 4 1 1 1
Blood pressure 4 2 1 2 1
Fasting blood glucose 0 5 1 2 2
Random blood glucose 2 4 0 3 1
HbA1c 2 2 1 2 3
Blood lipid proﬁle 2 4 0 2 2
Assessment of any movement disorders 2 4 2 0 2
Assessment of nutritional status, diet and level of physical activity 3 3 1 3 0
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Ongoing monitoring of weight and other physiological
measures
It was clear from the responses that there were variations in
recording patients’ weight at the time points recommended
by NICE (ﬁrst at 6 weeks post-treatment initiation, then at
12 weeks, at 1 year and annually thereafter), both between
trusts and within trust services. Some confusion exists
regarding responsibility for annual patient reviews in the
community and whether these should be completed by the
general practitioner (GP) or the trust. Half of those
surveyed reported that it was neither likely nor unlikely
that patients would have their weight recorded weekly for
the ﬁrst 6 weeks, with three other trusts reporting that this
was very unlikely. There was an even spread across all
response categories as to whether weight was recorded at 12
weeks, but at 1 year four of those surveyed reported that
patients were very likely to have their weight recorded. Six
respondents reported that weight was likely or very likely to
be recorded annually thereafter, although this was where the
confusion arose regarding responsibility for these reviews.
Table 3 shows trusts’ consideration as to how likely it
was that physiological measures would be recorded at least
annually in patients taking antipsychotic medication. One
site felt they were unable to answer this question, so we
present data reﬂecting responses from nine trusts.
There was no correlation between which of the
recommended physiological measures were recorded by
trusts prior to antipsychotic treatment initiation or
annually thereafter, although generally those trusts who
were likely to record particular measures prior to treatment
initiation were also likely to record the same measures at
least annually thereafter.
Discussion
Principal ﬁndings
It was clear from this survey that there was great variation
between different NHS mental health trusts in the provision
of healthy eating and physical activity interventions
routinely offered to patients, as well as variation between
clinicians within the same trust, with interventions often
accessed only through particular clinicians or clinics.
Commonly, trusts reported signposting or referring patients
to programmes offered by external services, such as gym
memberships and activity classes.
Most patients had access to a smoking cessation service
should they require it, and referrals to such services were
reported to occur most if not all of the time at nine out of
the ten trusts surveyed, regardless of whether the service
was offered within the trust or run externally.
When deciding on antipsychotic medication with newly
diagnosed patients, there was also variability in the reported
discussions that took place across trusts. All trusts reported
that the likely beneﬁts, weight gain, diabetes and metabolic
and other possible side-effects were discussed with the
patient at least some of the time; the possible interference
of other substances with prescribed antipsychotic medication
was also discussed.
Although at the early stages in the course of anti-
psychotic treatment it was reported unlikely that trusts would
record a patient’s weight, as recommended by NICE, by 1 year
after treatment initiation a larger proportion of trusts reported
weight recording, with an increase for annual reviews there-
after, despite the uncertainties regarding responsibility for
undertaking annual reviews in the community.
Study strengths and limitations
A strength of this survey was that its design was based on
the NICE guidelines to which mental health trusts should
be adhering. This meant that trusts’ compliance with these
recommendations could be assessed, allowing us to elicit
information on what programmes (if any) trusts were
offering in usual practice and how these compared with
what is recommended by NICE. This also allowed us to try
to deﬁne ‘usual care’ in relation to the STEPWISE study,
using a standard approach across all trusts.
The survey was, in principle, a suitable method to elicit
the same information from all respondents; however, it was
clear from the responses that owing to the variability of
services offered it was often difﬁcult to provide a succinct
account using this survey tool. The narrative information
provided by the respondents proved more useful in gaining
a fuller picture of their usual care than the descriptive
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Table 3 Recording of physiological measures at least annually for patients on antipsychotic medication (n=9 NHS trusts)
Very
likely Likely
Neither likely
or unlikely Unlikely
Very
unlikely
Weight 3 4 0 2 0
Weight plotted on a chart 0 3 3 2 1
Waist circumference 0 2 2 3 2
Pulse 2 4 1 1 1
Blood pressure 3 4 1 1 0
Fasting blood glucose 1 2 5 1 0
HbA1c 2 2 4 1 0
Blood lipid proﬁle 2 1 4 2 0
Assessment of any movement disorders 1 4 3 1 0
Assessment of nutritional status, diet and level of physical activity 3 1 3 2 0
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statistics, which in some cases were a best guess, as clear
data were not always available.
Furthermore, responses were based on one member of
staff’s knowledge of usual care in practice, and although this
person was usually best placed to answer the questions,
from the survey responses received knowledge may have
been limited, especially as some interventions offered were
particular to a speciﬁc clinic or clinician and usual care may
vary within and between community mental health teams in
any given NHS organisation. In addition, how representative
‘usual care’ is in comparison with NHS trusts not taking part
in the STEPWISE study remains unknown.
The levels of detail regarding the content of available
services also varied, perhaps indicating that the respondent
had more involvement with some programmes than others.
Therefore, it was considered likely that additional inter-
ventions may have been offered within trusts of which the
survey respondent was unaware.
In relation to implementation, a weakness in the survey
was highlighted when some responses were received
through telephone discussion while others were completed
by the respondent and returned to the researcher. No
systematic differences between telephone and paper copy
responses were identiﬁed, although more supporting
information was often provided through telephone
responses, as these were elicited through more of a
conversational discussion. This difference in response
methods may have caused questions to be perceived
differently, although all telephone participants had a copy
of the questionnaire available to them at the time of
completion. Perceptions of appropriate levels of detail can
change with different methods of completion, which may
lead to variation in results. However, as such variation was
evident between practices offered as ‘usual care’ in the ten
trusts surveyed, the impact of these differences in
completion method is considered likely to be small.
The variability in the information elicited has not allowed
for a common picture across all sites, as although a type of
programme is recommended by NICE, a particular standard-
ised programme is not available across all trusts. However, the
survey did provide sufﬁcient baseline information to allow any
changes in usual practice during the course of the STEPWISE
study to be monitored at a trust level, rather than across all
study sites as a whole. This will enable assessing at the end of
the STEPWISE study the extent of potential contamination
between the intervention and control arms of the trial, based
on changes in practice reported in the survey.
Context
Although there may be an increased awareness of the
potential beneﬁts of some treatments, this does not ensure
that such treatments are implemented effectively. Evaluations
and methods of improving the implementation of NICE
guidelines often have limited attention.13 A systematic
review undertaken by Berry & Haddock13 noted that the
research around the implementation of NICE guidelines on
schizophrenia is relatively limited, suggesting that these
patients have poor access to psychological interventions
such as cognitive-behavioural therapy (CBT). Some barriers
to implementation of NICE guidelines were reported, such
as insufﬁcient support from trust management and the
needs of organisations. The paper also highlights that
whereas NICE considers randomised controlled trials
(RCTs) to be the gold standard when developing an
evidence base for its guidelines, RCTs have also been
criticised for their poor ability to reﬂect the ‘real world’. The
authors suggest that targeting these barriers is key to
facilitating successful implementation of the guidelines.13
It is therefore important to identify which aspects of
the guidance are not currently being followed, in order to
target these areas for implementation and improve clinical
care. Not only is it important to consider the implementation
of guidance relating to monitoring of biomedical measures,
but there is also likely to be a limited effect unless this is
combined with sufﬁcient intervention in behaviour or
treatment. Similarly, the mere fact of guidance or a trial
does not necessarily lead to substantive changes or better
outcomes. Repeating the survey annually will allow
identiﬁcation of any substantive, systematic changes
within the organisations, both since the introduction of
the NICE guidelines and throughout the duration of the
STEPWISE trial.
From a research perspective, the reported variation
also has implications for our study when deﬁning ‘usual
care’. If all trusts adhered to all recommendations in the
NICE guidelines, we could be sufﬁciently conﬁdent that
contamination between trial arms would be minimal.
However, as different levels of compliance with different
recommendations were evident, this does not allow for
standardised ‘usual care’ across the study. This does mean
that usual practice can be compared over time within each
trust individually, in order to assess how much ‘usual care’
has changed throughout the course of their participation in
the STEPWISE study.
The Royal College of Psychiatrists’ National Audit of
Schizophrenia includes standards on the monitoring of
physical health in patients with schizophrenia. The audit
report in 2014 noted that the provision of interventions is
poor when there is evidence of physical health risks.14 It
highlighted barriers to intervention, such as availability of
staff time, facilities and equipment, the need for formal
systems to conduct annual reviews, and the need for more
formal arrangements regarding responsibility for physical
health between primary and secondary care.14 Standard 5 in
the audit speciﬁcally looks at interventions offered for
particular physical health risks. The overall results show
that intervention for BMI425 kg/m2 was evident in 71% of
patients, while interventions for smoking were reported in
59% of patients.14
For the ten trusts surveyed, the audit reported a range
of 47-83% of patients receiving intervention for elevated
BMI, and 33-67% receiving intervention for smoking.
Overall, the audit also showed wide variation in the
monitoring of physical health risk factors. For example,
the range across all participating trusts for monitoring of
BMI was 5-92% of patients and 16-99% for the monitoring
of glucose control. This is supportive of the information
yielded from the study survey and highlights variability in
services offered across trusts.14
ORIGINAL PAPER
Swaby et al Lifestyle advice for people with schizophrenia: a survey
5
Implications for stakeholders
This survey indicates that the ten sites surveyed are not
fully compliant with NICE physical health recommend-
ations on the management of patients with schizophrenia.
However, as the guidelines were published in March 2014,
this is not surprising, because services require time to
commission and set up. In some respects, this alleviates the
concerns that the ‘usual care’ arm of the STEPWISE trial
may converge with the intervention arm, as there are no
reported standardised programmes offered across any of the
trusts surveyed. However, there is such variability observed
that it becomes clear that ‘usual care’ is not the same for all
participants in the trial or in the wider population group.
We have not tried to assess the success or potential
effect of any one aspect of the physical health programme in
comparison with others. Although it may be argued that
smoking cessation could have a greater effect on physical
health than healthy eating or physical activity programmes,
despite the lower compliance with NICE guidance, any
discussion is likely to be subjective. Furthermore, NICE
does not prioritise any one element, coming from an
understanding that all aspects are important and contribute
to improved physical health.
As a future direction, it may be useful to try to
identify patients at higher risk of cardiovascular events,
using recording of cardiovascular disease risk factors in
combination with risk engines to calculate risk accurately.
This identiﬁcation process could then drive intervention.
This may be of interest to trusts as a method of offering a
physical health intervention to those patients who are likely
to receive the most beneﬁt clinically. A suitable risk engine
to calculate this would be the PRIMROSE cardiovascular
disease algorithm,15 as this has been developed speciﬁcally
for people with severe mental illness. The PRIMROSE
model includes additional variables for psychiatric diagnosis,
psychotropic medication, harmful use of alcohol, anti-
depressants and social deprivation score, unlike similar
prediction models used in the general population. This is
perhaps why PRIMROSE performed better than some other
available published risk models, which may overpredict the
risk of cardiovascular disease in this population.15
Further research
The survey will be repeated with the same ten NHS trust
representatives at 12 and 24 months after the ﬁrst iteration.
This will allow the STEPWISE study team to consider
how trusts are implementing the NICE guidelines and,
consequently, whether convergence has occurred between
the two arms of the STEPWISE trial at an individual trust
level. As STEPWISE progresses, the participating NHS
organisations may become more aware of the need to
undertake physical health interventions and so ‘usual care’
may improve, potentially diminishing the effect of the
STEPWISE intervention.
Appendix
Routine Usual Weight and Lifestyle Management Care
for patients with ﬁrst episode psychosis, schizophrenia
or schizoaffective disorder*
Site: ______________________________ Date of completion: __/__/__
Role of person completing:
______________________________________________________________
1. Does your Trust offer a healthy eating and physical activity
programme?
a. Combined healthy eating and physical activity programme C
b. Separate healthy eating and physical activity programmes C
c. Healthy eating programme only C
d. Physical activity programme only C
e. None C
2. If a programme is offered, which patients can be referred to the
programme?
a. All patients C
b. Patients with psychosis or schizophrenia C
3. What proportion of eligible patients are referred?
______________________________________________________________
______________________________________________________________
4. What proportion of patients referred, attend the programme?
______________________________________________________________
______________________________________________________________
5. If a programme is offered, how is this accessed?
a. Ongoing course C
b. Drop-in sessions C
c. Over a ﬁxed period C
d. Other C
(please give details) _________________________________________
6. If a healthy eating and/or physical activity programme is offered
by your Trust (a, b, c or d in Q1), please provide the name of the
programme and appropriate contact details for a programme
representative:
7. Does your Trust offer people with psychosis or schizophrenia who
smoke, help to stop smoking, even if previous attempts have been
unsuccessful?
a. All of the time C
b. Some of the time C
(please state how often) _____________________________________
c. Not at all C
8. If yes, is this help provided by your Trust, or an external smoking
cessation service?
______________________________________________________________
9. If a smoking cessation/advice programme is offered by your Trust,
please provide the name of the programme and appropriate contact
details for a programme representative:
10. How often are the following discussed with the patient when
deciding on antipsychotic treatment?
All of Some of
the time the time Not at all
Likely beneﬁts C C C
Weight gain C C C
Diabetes andmetabolic side effects C C C
Other possible side effects C C C
Please use the space below to provide further details (if applicable)
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11. How often is the use of the following, and their possible
interference with prescribed medication discussed with the patient?
All of Some of
the time the time Not at all
Alcohol C C C
Tobacco C C C
Other prescribed medications C C C
Non-prescribed medications C C C
Illicit drugs C C C
Please use the space below to provide further details (if applicable)
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Please Note: Questions 12 & 13 relate specifically to patients with first episode psychosis.
12. How likely is it that patients will have the following recorded before they start taking antipsychotic medication?
Very
likely Likely
Neither likely
or unlikely Unlikely
Very
unlikely
Weight
Weight plotted on a chart
Waist circumference
Pulse
Blood pressure
Fasting blood glucose
Random blood glucose
HbA1c
Blood lipid proﬁle
Assessment of any movement disorders
Assessment of nutritional status, diet and level of physical activity
13. How likely is it that patients will have their weight recorded as follows?
Very
likely Likely
Neither likely
or unlikely Unlikely
Very
unlikely
Weekly for the ﬁrst 6 weeks
At 12 weeks
At 1 year
Annually thereafter
If any of the above are unlikely or very unlikely,
is there a reason this is not recorded?
Q14 relates to all patients (first episode psychosis, schizophrenia and schizoaffective disorder)
14. How likely is it that patients will have the following recorded at least annually?
Very
likely Likely
Neither likely
or unlikely Unlikely
Very
unlikely
Weight
Weight plotted on a chart
Waist circumference
Pulse
Blood pressure
Fasting blood glucose
HbA1c
Blood lipid proﬁle
Assessment of any movement disorders
Assessment of nutritional status, diet and level of physical activity
Other comments:
*The questionnaire is freely available by contacting the corresponding author.
7
Funding
The STEPWISE trial was funded by the National Institute for Health
Research Health Technology Assessment programme (project number 12/
28/05). The views and opinions expressed therein are those of the authors
and do not necessarily reﬂect those of Health Technology Assessment
programme, NIHR, NHS or the Department of Health. The STEPWISE trial is
sponsored by Shefﬁeld Health and Social Care NHS Foundation Trust.
Acknowledgements
We acknowledge the STEPWISE research group: Katharine Barnard,
University of Southampton; Michael Bradburn, University of Shefﬁeld;
Marian Carey, University Hospitals of Leicester NHS Trust; Heather Daly,
University Hospitals of Leicester NHS Trust; Melanie Davies, University of
Leicester; Christopher M. Dickens, University of Exeter; Angela Etherington,
PPI representative; Paul French, Greater Manchester West Mental Health
NHS Foundation Trust; Fiona Gaughran, South London and Maudsley NHS
Foundation Trust; Tim Kendall, Royal College of Psychiatrists; Kamlesh
Khunti, University of Leicester; Richard Laugharne, Cornwall Partnership
NHS Foundation Trust; Paul McCrone, King’s College London; John
Pendlebury, Greater Manchester West Mental Health NHS Foundation
Trust; Shanaya Rathod, Southern Health NHS Foundation Trust; Stephen
Wright, Leeds and York Partnership NHS Foundation Trust; Thomas Yates,
University of Leicester; Kathy Greenwood, Sussex Partnership NHS
Foundation Trust; Sridevi Kalidindi, South London and Maudsley NHS
Foundation Trust; Najma Siddiqi, Bradford District Care NHS Foundation
Trust; Glenn Waller, University of Shefﬁeld. We would also like to
acknowledge those individuals who contributed to and coordinated the
survey responses at each trust.
About the authors
Lizzie Swaby is Research Assistant, Daniel Hind is Senior Research Fellow
and Assistant Director, and Rebecca Gossage-Worrall is Research Associate,
all at Shefﬁeld Clinical Trials Research Unit, University of Shefﬁeld. David
Shiers is Honorary Reader in Early Psychosis, Division of Psychology and
Mental Health, University of Manchester. Jonathan Mitchell is Consultant
Psychiatrist, Shefﬁeld Health and Social Care NHS Foundation Trust, Fulwood
House, Shefﬁeld. Richard I.G.Holt is Professor in Diabetes and Endocrinology,
Human Development and Health Academic Unit, Faculty of Medicine,
University of Southampton, and Honorary Consultant Physician at University
Hospital Southampton NHS Foundation Trust, Southampton, UK.
References
1 Homel P, Casey D, Allison DB. Changes in body mass index for
individuals with and without schizophrenia, 1987-1996. Schizophr Res
2002; 55: 277-84.
2 Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y,
Keet IPM, et al. Effectiveness of antipsychotic drugs in ﬁrst-episode
schizophrenia and schizophreniform disorder: an open randomised
clinical trial. Lancet 2008; 371: 1085-97.
3 McCreadie R, Macdonald E, Blacklock C, Tilak-Singh D, Wiles D,
Halliday J, et al. Dietary intake of schizophrenic patients in Nithsdale,
Scotland: case-control study. BMJ 1998; 317: 784-5.
4 Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of
people with schizophrenia. Psychol Med 1999; 29: 697-701.
5 Kilbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC.
Nutrition and exercise behavior among patients with bipolar disorder.
Bipolar Disord 2007; 9: 443-52.
6 Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in
patients with schizophrenia: implications for metabolic disturbances
and treatment with second-generation antipsychotic agents.
Neuropsychopharmacology 2006; 31: 2091-120.
7 Godfrey R, Julien M. Urbanisation and health. Clin Med 2005; 5: 137-41.
8 National Collaborating Centre for Mental Health. Psychosis and
Schizophrenia in Adults: Treatment and Management (Clinical Guideline
CG178). National Institute for Health and Care Excellence, 2014.
9 Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD,
Altman DG, et al. A pragmatic-explanatory continuum indicator
summary (PRECIS): a tool to help trial designers. J Clin Epidemiol
2009; 62: 464-75.
10 Ayling K, Brierley S, Johnson B, Heller S, Eiser C. How standard is
standard care? Exploring control group outcomes in behaviour change
interventions for young people with type 1 diabetes. Psychol Health 2015;
30: 85-103.
11 Burns T. End of the road for treatment-as-usual studies? Br J Psychiatry
2009; 195: 5-6.
12 Oberje´ EJM, Dima AL, Pijnappel FJ, Prins JM, de Bruin M. Assessing
treatment-as-usual provided to control groups in adherence trials:
exploring the use of an open-ended questionnaire for identifying
behaviour change techniques. Psychol Health 2015; 30: 897-910.
13 Berry K, Haddock G. The implementation of the NICE guidelines for
schizophrenia: barriers to the implementation of psychological
interventions and recommendations for the future. Psychol Psychother
2008; 81: 419-36.
14 Royal College of Psychiatrists. Report of the Second Round of the National
Audit of Schizophrenia (NAS). RCPsych, 2014.
15 Osborn DP, Hardoon S, Omar RZ, Holt RI, King M, Larsen J, et al.
Cardiovascular risk prediction models for people with severe mental
illness: results from the prediction and management of cardiovascular
risk in people with severe mental illnesses (PRIMROSE) research
program. JAMA Psychiatry 2015; 72: 143-51.
ORIGINAL PAPER
Swaby et al Lifestyle advice for people with schizophrenia: a survey
8
